Camurus AB (publ) (CAMX.ST)
SEK 537.0
(3.27%)
SEK 537.0
(3.27%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.05 Billion SEK | 34.07% |
| 2022 | 781.81 Million SEK | 24.58% |
| 2021 | 627.57 Million SEK | 23.71% |
| 2020 | 507.28 Million SEK | 14.66% |
| 2019 | 442.4 Million SEK | 33.95% |
| 2018 | 330.27 Million SEK | 11.83% |
| 2017 | 295.32 Million SEK | 37.53% |
| 2016 | 214.73 Million SEK | -40.02% |
| 2015 | 358 Million SEK | 142.46% |
| 2014 | 147.65 Million SEK | 99.08% |
| 2013 | 74.17 Million SEK | 3.5% |
| 2012 | 71.66 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 311 Million SEK | -12.35% |
| 2024 Q2 | 324.47 Million SEK | 4.33% |
| 2023 Q3 | 247.94 Million SEK | -7.9% |
| 2023 Q1 | 180.9 Million SEK | -18.45% |
| 2023 FY | 1.04 Billion SEK | 34.07% |
| 2023 Q4 | 354.84 Million SEK | 43.11% |
| 2023 Q2 | 269.21 Million SEK | 48.81% |
| 2022 Q4 | 221.83 Million SEK | 26.07% |
| 2022 Q1 | 189.3 Million SEK | 8.44% |
| 2022 Q2 | 194.7 Million SEK | 2.85% |
| 2022 Q3 | 175.96 Million SEK | -9.62% |
| 2022 FY | 781.81 Million SEK | 24.58% |
| 2021 Q4 | 174.56 Million SEK | 25.26% |
| 2021 Q2 | 177.08 Million SEK | 29.68% |
| 2021 Q1 | 136.55 Million SEK | -22.42% |
| 2021 FY | 627.57 Million SEK | 23.71% |
| 2021 Q3 | 139.36 Million SEK | -21.3% |
| 2020 Q3 | 113 Million SEK | 13.21% |
| 2020 Q4 | 176.01 Million SEK | 55.76% |
| 2020 FY | 507.28 Million SEK | 14.66% |
| 2020 Q1 | 118.44 Million SEK | 7.72% |
| 2020 Q2 | 99.81 Million SEK | -15.73% |
| 2019 Q1 | 99.92 Million SEK | -7.15% |
| 2019 Q3 | 112.78 Million SEK | -5.8% |
| 2019 FY | 442.4 Million SEK | 33.95% |
| 2019 Q2 | 119.73 Million SEK | 19.82% |
| 2019 Q4 | 109.95 Million SEK | -2.51% |
| 2018 Q4 | 107.61 Million SEK | 41.82% |
| 2018 FY | 330.27 Million SEK | 11.83% |
| 2018 Q3 | 75.88 Million SEK | -12.73% |
| 2018 Q2 | 86.95 Million SEK | 46.09% |
| 2018 Q1 | 59.52 Million SEK | -15.59% |
| 2017 FY | 295.32 Million SEK | 37.53% |
| 2017 Q4 | 70.51 Million SEK | -11.92% |
| 2017 Q3 | 80.05 Million SEK | 5.16% |
| 2017 Q2 | 76.12 Million SEK | 10.89% |
| 2017 Q1 | 68.64 Million SEK | -5.25% |
| 2016 Q2 | 51.41 Million SEK | 18.49% |
| 2016 Q3 | 46.56 Million SEK | -9.44% |
| 2016 Q4 | 72.44 Million SEK | 55.6% |
| 2016 FY | 214.73 Million SEK | -40.02% |
| 2016 Q1 | 43.39 Million SEK | -42.9% |
| 2015 Q1 | 45.43 Million SEK | -10.14% |
| 2015 Q2 | 168.68 Million SEK | 271.28% |
| 2015 Q3 | 66.25 Million SEK | -60.72% |
| 2015 Q4 | 75.99 Million SEK | 14.71% |
| 2015 FY | 358 Million SEK | 142.46% |
| 2014 FY | 147.65 Million SEK | 99.08% |
| 2014 Q4 | 50.56 Million SEK | 40.38% |
| 2014 Q3 | 36.01 Million SEK | 0.0% |
| 2013 FY | 74.17 Million SEK | 3.5% |
| 2012 FY | 71.66 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 30.02% |
| Mendus AB (publ) | 129.13 Million SEK | -720.57% |
| Lipum AB (publ) | 37.3 Million SEK | -2740.376% |
| NextCell Pharma AB | -576.01 Thousand SEK | 184062.508% |
| Simris Alg AB (publ) | 38.64 Million SEK | -2642.247% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -3640.896% |
| Active Biotech AB (publ) | 44.8 Million SEK | -2264.835% |
| Amniotics AB (publ) | 29.07 Million SEK | -3544.947% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -7131.687% |
| BioArctic AB (publ) | 89.62 Million SEK | -1082.299% |
| Cantargia AB (publ) | 290.01 Million SEK | -265.378% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -4739.731% |
| CombiGene AB (publ) | 44.14 Million SEK | -2300.454% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -641.088% |
| Genovis AB (publ.) | 88.19 Million SEK | -1101.468% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -820.858% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -14479.788% |
| Intervacc AB (publ) | 79.78 Million SEK | -1228.143% |
| Kancera AB (publ) | 63.07 Million SEK | -1579.945% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -19100.199% |
| LIDDS AB (publ) | 27.75 Million SEK | -3718.316% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -14507.927% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -679.666% |
| OncoZenge AB (publ) | 15.9 Million SEK | -6562.427% |
| Saniona AB (publ) | 1.07 Million SEK | -98289.879% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | -229.592% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | -196.306% |
| Xintela AB (publ) | 57.31 Million SEK | -1748.801% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -483.082% |
| Ziccum AB (publ) | 27.87 Million SEK | -3701.058% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -6360.941% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -245.065% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -2385.595% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -5892.53% |
| Corline Biomedical AB | 30.16 Million SEK | -3412.527% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -1726.022% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -1174.103% |
| Aptahem AB (publ) | 10.01 Million SEK | -10482.892% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -686.716% |
| Fluicell AB (publ) | 28.61 Million SEK | -3602.9% |
| Biovica International AB (publ) | 133.72 Million SEK | -692.434% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -5254.517% |
| AcouSort AB (publ) | 25.87 Million SEK | -3995.142% |
| Abliva AB (publ) | 27.86 Million SEK | -3702.695% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -447.627% |
| 2cureX AB (publ) | 36.51 Million SEK | -2801.744% |
| I-Tech AB | 40.14 Million SEK | -2539.382% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | -23.295% |
| Cyxone AB (publ) | 28.21 Million SEK | -3655.791% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -868.893% |
| Biosergen AB | 26.8 Million SEK | -3852.624% |
| Nanologica AB (publ) | 69.88 Million SEK | -1416.246% |
| SynAct Pharma AB | 224.49 Million SEK | -372.017% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -2298.721% |
| BioInvent International AB (publ) | 441.4 Million SEK | -140.066% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -4323.675% |
| Alzinova AB (publ) | 36.39 Million SEK | -2811.471% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -265.72% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -13388.069% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -855.388% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -7108.565% |